Origin Therapeutics’ Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland

[AJBot]

The clinical trial, titled CLA-PSY-201, will evaluate the safety and efficacy of a 25 mg synthetic psilocybin capsule versus placebo, with Motivational Enhancement Therapy (MET). Following the approval from FIMEA, Clairvoyant has launched the first of four planned trial sites in Finland. In total, the clinical trial will be initiated in approximately 15 sites across Canada and Europe with the first site in Canada initiated in June of 2022. Several potential patients have already entered the screening process for the trial. Read More ...

Continue reading the above news article, by clicking here.

Administration and Moderation NOTE: A Reminder, the above news is provided for free, through a RSS Feed. The above quote does NOT include the full story. In order to continue to read more past what is quoted, please click through to the article, by clicking on the link provided above through the "continue reading" text.

Please be sensible and follow our terms of service and rules, when replying and debating the news article.